Squaric acid dibutyl ester for the treatment of alopecia areata: A retrospective evaluation

  title={Squaric acid dibutyl ester for the treatment of alopecia areata: A retrospective evaluation},
  author={Enkhjargal Losol and Nilg{\"u}n Şent{\"u}rk},
  journal={Dermatologic Therapy},
Squaric acid dibutyl ester (SADBE) as topical immunotherapy is a good alternative in patients with refractory alopecia areata. In this study, we aimed to evaluate the effectiveness of SADBE treatment in alopecia areata (AA) and alopecia totalis/alopecia universalis (AT/AU) patients and determine the prognostic factors affecting treatment response. Data obtained from 34 (AA/AT/AU) patients treated with SADBE were analyzed retrospectively. Of the 34 patients, 16 (47.1%) were female and 18 (52.9… 


Seasonal patterns in alopecia areata, totalis, and universalis
There might be a seasonal pattern, a predilection for flares during colder months; to what degree remains unclear, in AA patients with atopy or historically cyclic flare patterns, it may be reasonable to recommend prophylactic antihistamine therapy during high-risk flare months.
Vitamin D and alopecia areata: possible roles in pathogenesis and potential implications for therapy.
The possible roles of vitamin D in the pathogenesis of alopecia areata are discussed in the context of loss of immune privilege in hair follicle, autoreactive effector T cells and mast cells, nature killer group 2 member d-positive cytotoxic T cells, and oxidative stress.
Alopecia areata update.
Alopecia areata (AA) is a common nonscarring alopecia. It affects 1.7% of the population at some point in their lives. AA is an autoimmune condition characterized by dense peribulbar lymphocytic
Efficacy of topical sensitizers in the treatment of alopecia areata.
The efficacy and safety of the use of topical sensitizers in the treatment of alopecia areata and squaric acid dibutylester are reviewed.
Alopecia areata.
Alopecia areata is an asymptomatic, nonscarring hair loss with spontaneous remissions and exacerbations that is associated with vitiligo, atopy, pernicious anemia, Down syndrome and thyroiditis.
Alopecia areata investigational assessment guidelines-Part II
This National Alopecia Areata Foundation sponsored subgroup of investigators/clinicians experienced in clinical trials and/or in the clinical care of patients with alopecIA areata has outlined some general principles and potential endpoints for clinical studies in alopECia areata.
Topical immunotherapy of alopecia areata.
Topical immunotherapy has proven to be a highly rewarding treatment modality for extensive forms of AA. The method should be considered at this time to be in an experimental stage, and therefore
Epidermal Growth Factor Promotes Proliferation and Migration of Follicular Outer Root Sheath Cells via Wnt/β-Catenin Signaling
EGF promotes the proliferation and migration of ORS cells and modulates the expression of several follicle-regulatory genes via Wnt/β-catenin signaling.
Alopecia areata. Nat Rev Dis Primers
  • 2017
SADBE efficiency in the treatment of patients with alopecia areata in the ophiasic model
  • Dermatoz
  • 2010